Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Timolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.85 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | HTR1A | P08908 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | DRD1 | P21728 | 1/20 | 0.85 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timolol SCHEMBL6828541 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL1629068 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL28427209 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL8093958 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL1588402 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL1428194 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL41823 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL30597567 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL365528 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 | |
| Timolol SCHEMBL365527 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2BLMCYP1A2ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12169 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854885-B1 | PHARMACOGENOMIC SCREENING METHOD FOR ANTICIPATING A PATIENT'S RESPONSE TO THE TREATMENT OF OCULAR HYPERTENSION | CANUT JORDANA MARIA ISABEL (ES) | 2026-05-06 | — | — | EP | claimed |
| US-12599607-B2 | Pharmaceutical compositions comprising timolol | NOVALIQ GMBH (DE) | 2026-04-14 | — | — | US | claimed |
| EP-4713460-A1 | APTAMERS FOR THE DETECTION OF DRUGS, BIOMARKERS, AND SMALL MOLECULES FOR OCULAR APPLICATIONS | Centre For Eye And Vision Research Limited (HK) | 2026-03-25 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| CN-121570441-A | Timolol maleate gel emplastrum and preparation method thereof | 云南白药集团无锡药业有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4691568-A2 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | Eye Therapies, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| US-20260013482-A1 | METHOD FOR CONSTRUCTING AN ANIMAL MODEL OF OPEN-ANGLE GLAUCOMA | THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY (CN) | 2026-01-15 | — | — | US | claimed |
| US-20250387325-A1 | FIXED DOSE COMBINATION OF BRIMONIDINE AND TIMOLOL | ALLERGAN INC (US) | 2025-12-25 | — | — | US | claimed |
| US-12472273-B2 | Sterilization process of timolol gel forming solution through aseptic filtration | SENTISS PHARMA PRIVATE LIMITED (IN) | 2025-11-18 | — | — | US | claimed |
| US-4861760-A | Ophthalmological composition of the type which undergoes liquid-gel phase transition | MERCK & CO., INC. (US) | 1989-08-29 | — | — | US | claimed |
| EP-0286903-A1 | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1988-10-19 | — | — | EP | claimed |
| EP-0253717-A1 | Combinations of beta-blockers and pilocarpine | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET (FR) | 1988-01-20 | — | — | EP | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| US-4560553-A | THERAPEUTIC, COSMETIC;MIXTURES OF HYPOTENSIVES, ANESTHETICS, BETA-BLOCKERS AND MICROBIOCIDES | MERCK & CO., INC. (US) | 1985-12-24 | — | — | US | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |
| EP-0147780-A2 | Drug delivery device | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |